Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 208.33
NLNK's Cash to Debt is ranked higher than
54% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. NLNK: 208.33 )
Ranked among companies with meaningful Cash to Debt only.
NLNK' s Cash to Debt Range Over the Past 10 Years
Min: 1.05  Med: 10.09 Max: 208.33
Current: 208.33
1.05
208.33
Equity to Asset 0.90
NLNK's Equity to Asset is ranked higher than
83% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NLNK: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
NLNK' s Equity to Asset Range Over the Past 10 Years
Min: -3.25  Med: 0.68 Max: 0.9
Current: 0.9
-3.25
0.9
F-Score: 4
Z-Score: 13.83
WACC vs ROIC
15.37%
-262.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -49.05
NLNK's Operating margin (%) is ranked higher than
53% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. NLNK: -49.05 )
Ranked among companies with meaningful Operating margin (%) only.
NLNK' s Operating margin (%) Range Over the Past 10 Years
Min: -2849.13  Med: -1036.44 Max: 68.12
Current: -49.05
-2849.13
68.12
Net-margin (%) -58.95
NLNK's Net-margin (%) is ranked higher than
52% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. NLNK: -58.95 )
Ranked among companies with meaningful Net-margin (%) only.
NLNK' s Net-margin (%) Range Over the Past 10 Years
Min: -2852.7  Med: -1017.04 Max: 55.63
Current: -58.95
-2852.7
55.63
ROE (%) -19.07
NLNK's ROE (%) is ranked higher than
60% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. NLNK: -19.07 )
Ranked among companies with meaningful ROE (%) only.
NLNK' s ROE (%) Range Over the Past 10 Years
Min: -85.27  Med: -51.18 Max: 75.23
Current: -19.07
-85.27
75.23
ROA (%) -17.13
NLNK's ROA (%) is ranked higher than
60% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. NLNK: -17.13 )
Ranked among companies with meaningful ROA (%) only.
NLNK' s ROA (%) Range Over the Past 10 Years
Min: -75.86  Med: -59.94 Max: 63.63
Current: -17.13
-75.86
63.63
ROC (Joel Greenblatt) (%) -149.17
NLNK's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. NLNK: -149.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NLNK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -475.32  Med: -352.62 Max: 1042.38
Current: -149.17
-475.32
1042.38
Revenue Growth (3Y)(%) 209.30
NLNK's Revenue Growth (3Y)(%) is ranked higher than
98% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NLNK: 209.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NLNK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 209.3
Current: 209.3
0
209.3
EBITDA Growth (3Y)(%) 1.10
NLNK's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. NLNK: 1.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NLNK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.1
Current: 1.1
0
1.1
EPS Growth (3Y)(%) 8.00
NLNK's EPS Growth (3Y)(%) is ranked higher than
67% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NLNK: 8.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NLNK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 8
Current: 8
0
8
» NLNK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

NLNK Guru Trades in Q2 2015

Joel Greenblatt 1,244,856 sh (+48.51%)
First Eagle Investment 1,719,600 sh (+20.19%)
Paul Tudor Jones 5,700 sh (+5.95%)
First Eagle Investment 7,597 sh (unchged)
» More
Q3 2015

NLNK Guru Trades in Q3 2015

Jim Simons 158,073 sh (New)
First Eagle Investment 1,876,600 sh (+9.13%)
First Eagle Investment 9,971 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2015

NLNK Guru Trades in Q4 2015

Paul Tudor Jones 6,300 sh (New)
First Eagle Investment 7,770 sh (unchged)
Samuel Isaly 138,300 sh (unchged)
First Eagle Investment 1,793,200 sh (-4.44%)
Jim Simons 56,921 sh (-63.99%)
» More
2016

NLNK Guru Trades in 2016

Samuel Isaly 138,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about NewLink Genetics Corp

First Eagle Investment Adds to Stake in NewLink Genetics Stock price is close to one-year low
First Eagle is an independent firm that was originally founded in 1864 by the Arnhold brothers in Dresden, Germany. In 1931, the firm acquired S. Bleichröder and moved the company to New York City in 1937 and began conducting business under the name of Arnhold and S. Bleichroeder Inc. Read more...

Ratios

vs
industry
vs
history
P/B 2.31
NLNK's P/B is ranked higher than
63% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. NLNK: 2.31 )
Ranked among companies with meaningful P/B only.
NLNK' s P/B Range Over the Past 10 Years
Min: 2.31  Med: 7.24 Max: 21.18
Current: 2.31
2.31
21.18
P/S 7.04
NLNK's P/S is ranked higher than
60% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. NLNK: 7.04 )
Ranked among companies with meaningful P/S only.
NLNK' s P/S Range Over the Past 10 Years
Min: 4.56  Med: 143.10 Max: 1056.82
Current: 7.04
4.56
1056.82
Current Ratio 14.03
NLNK's Current Ratio is ranked higher than
84% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. NLNK: 14.03 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s Current Ratio Range Over the Past 10 Years
Min: 4.01  Med: 6.92 Max: 16.5
Current: 14.03
4.01
16.5
Quick Ratio 14.03
NLNK's Quick Ratio is ranked higher than
84% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NLNK: 14.03 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s Quick Ratio Range Over the Past 10 Years
Min: 4.01  Med: 6.92 Max: 16.5
Current: 14.03
4.01
16.5
Days Sales Outstanding 28.71
NLNK's Days Sales Outstanding is ranked higher than
80% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. NLNK: 28.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
NLNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.42  Med: 153.75 Max: 617.06
Current: 28.71
26.42
617.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.65
NLNK's Price/Net Cash is ranked higher than
75% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. NLNK: 2.65 )
Ranked among companies with meaningful Price/Net Cash only.
NLNK' s Price/Net Cash Range Over the Past 10 Years
Min: 5.21  Med: 7.12 Max: 29.76
Current: 2.65
5.21
29.76
Price/Net Current Asset Value 2.47
NLNK's Price/Net Current Asset Value is ranked higher than
77% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. NLNK: 2.47 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NLNK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.66  Med: 5.87 Max: 21.93
Current: 2.47
4.66
21.93
Price/Tangible Book 2.34
NLNK's Price/Tangible Book is ranked higher than
70% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. NLNK: 2.34 )
Ranked among companies with meaningful Price/Tangible Book only.
NLNK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.94  Med: 5.65 Max: 14.64
Current: 2.34
3.94
14.64
Price/Projected FCF 2.87
NLNK's Price/Projected FCF is ranked higher than
57% of the 172 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. NLNK: 2.87 )
Ranked among companies with meaningful Price/Projected FCF only.
NLNK' s Price/Projected FCF Range Over the Past 10 Years
Min: 6.58  Med: 6.58 Max: 6.58
Current: 2.87
Price/Median PS Value 0.05
NLNK's Price/Median PS Value is ranked higher than
98% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NLNK: 0.05 )
Ranked among companies with meaningful Price/Median PS Value only.
NLNK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.98 Max: 3.49
Current: 0.05
0.05
3.49
Price/Graham Number 0.83
NLNK's Price/Graham Number is ranked lower than
99.99% of the 292 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. NLNK: 0.83 )
Ranked among companies with meaningful Price/Graham Number only.
NLNK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.8  Med: 1.80 Max: 1.8
Current: 0.83
Earnings Yield (Greenblatt) (%) -12.74
NLNK's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. NLNK: -12.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NLNK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -12.74  Med: 11.60 Max: 16.7
Current: -12.74
-12.74
16.7

More Statistics

Revenue(Mil) $69
EPS $ -1.44
Beta1.80
Short Percentage of Float29.82%
52-Week Range $15.68 - 56.16
Shares Outstanding(Mil)28.86

Analyst Estimate

Dec16
Revenue(Mil)
EPS($) -2.90
EPS without NRI($) -2.90

Business Description

Industry: Biotechnology » Biotechnology
Compare:XBRU:ABLX, NAS:CHRS, NAS:DVAX, SZSE:300181, SZSE:300381, OSTO:RECI B » details
Traded in other countries:4NX.Germany,
NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The Company is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its products include biologic and small-molecule immunotherapy product candidates intended to treat oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The Company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The Company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically-resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator-initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non-patient specific) cells from previously established cell lines rather than cells derived from the patient. The Company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The Company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The Company is subject to federal, state, local and foreign regulation.
» More Articles for NLNK

Headlines

Articles On GuruFocus.com
First Eagle Investment Adds to Stake in NewLink Genetics Feb 03 2016 
These Companies Show High Profit and Low Debt Jun 17 2015 
When A Stock Doubles, Don’t Trim It Automatically May 27 2015 
Greenblatt's Top Buys During First Quarter May 22 2015 
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Other Websites
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 25 2016
NewLink Genetics Awarded $21.6 Million Contract Option by BARDA for Ebola Vaccine Development Apr 25 2016
NewLink Genetics Awarded $21.6 Million Contract Option by BARDA for Ebola Vaccine Development Apr 25 2016
NewLink Genetics to Host Its First Quarter 2016 Earnings Conference Call on April 29, 2016 Apr 21 2016
NewLink Genetics to Host Its First Quarter 2016 Earnings Conference Call on April 29, 2016 Apr 21 2016
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 15 2016
NewLink Genetics Receives $2.8 Million Award from DTRA to Develop a Multivalent Filovirus Vaccine Apr 15 2016
NewLink Genetics Receives $2.8 Million Award from DTRA to Develop a Multivalent Filovirus Vaccine Apr 15 2016
ETF’s with exposure to NewLink Genetics Corp. : April 14, 2016 Apr 14 2016
NewLink Genetics to Participate in Two Upcoming Investor Conferences Apr 06 2016
NewLink Genetics to Participate in Two Upcoming Investor Conferences Apr 06 2016
NEWLINK GENETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 24 2016
Coverage initiated on NewLink Genetics by Robert W. Baird Mar 23 2016
ETF’s with exposure to NewLink Genetics Corp. : March 22, 2016 Mar 22 2016
Put sellers bet on end to NewLink drop Mar 11 2016
The 52-Week Low Club for Monday Mar 07 2016
NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 07 2016
[$$] Drugmakers Scramble to Find Zika Vaccine Mar 07 2016
[$$] Drugmakers Scramble to Find Zika Vaccine Mar 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK